Healthcare -
Biotechnology - NASDAQ - US
$ 0.9632
1.38 %
$ 43.7 M
Market Cap
-0.94
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart PDSB
FINANCIALS
Balance Sheet
PDS Biotechnology Corporation
| Current Assets | 45.1 B |
| Cash & Short-Term Investments | 41.7 B |
| Receivables | 0 |
| Other Current Assets | 3.36 B |
| Non-Current Assets | 304 M |
| Long-Term Investments | 0 |
| PP&E | 304 K |
| Other Non-Current Assets | 304 M |
| Current Liabilities | 17.1 B |
| Accounts Payable | 1.68 M |
| Short-Term Debt | 12.6 B |
| Other Current Liabilities | 4.52 B |
| Non-Current Liabilities | 9.27 B |
| Long-Term Debt | 9.27 M |
| Other Non-Current Liabilities | 9.26 B |
EFFICIENCY
Earnings Waterfall
PDS Biotechnology Corporation
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 36.3 B |
| Operating Income | -36.3 B |
| Other Expenses | 1.29 B |
| Net Income | -37.6 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
PDS Biotechnology Corporation
| Net Income | -37.6 B |
| Depreciation & Amortization | 1.16 B |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 6.85 M |
| Change in Working Capital | -5.75 M |
| Others | 1.42 B |
| Free Cash Flow | -35 B |
Wall Street Analysts Price Targets
PDS Biotechnology Corporation
Wall Street analysts predict an average 1-year price target for PDSB of $9 , with forecasts ranging from
a
low of
$9 to a high of $9 .
PDSB Lowest Price Target
Wall Street Target
9 USD
834.39%
PDSB Average Price Target
Wall Street Target
9 USD
834.39%
PDSB Highest Price Target
Wall Street Target
9 USD
834.39%
4. DIVIDEND
ANALYSIS
PDSB does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
PDS Biotechnology Corporation
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
96.1 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Tom Johnson - LifeSci Advisors Frank Bedu-Addo - CEO Kirk Shepard - Chief Medical Officer Lars Boesgaard - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright Mayank Mamtani - B.
seekingalpha.com
- 3 weeks ago
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Initiated VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune ® HPV in HPV16-Positive Head and Neck Cancer
globenewswire.com
- 3 weeks ago
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
PRINCETON, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.
globenewswire.com
- 3 weeks ago
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
PRINCETON, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the year ended December 31, 2024, and provide a clinical programs update on Thursday, March 27, 2025, at 8:00 a.m.
globenewswire.com
- 1 month ago
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer Institute Second Versamune ® platform candidate targets MUC1-positive solid tumors U.S. Patent #12,201,685 covering methods of using combinations of the Versamune ® platform and various immunocytokines, including PDS01ADC recently issued PRINCETON, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (“IND”) application filed in January 2025 to evaluate a combination of Versamune® MUC1 (formerly PDS0103), its novel investigational MUC1-targeted immunotherapy candidate + PDS01ADC to treat MUC1-positive unresectable, metastatic colorectal carcinoma (“mCRC”) in patients who failed previous treatment.
globenewswire.com
- 1 month ago
PDS Biotech Leadership to Participate in March Conferences
PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech, will present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, and the 2025 Cancer Advocacy Group of Louisiana (CAGLA) NeauxCancer Conference in New Orleans on Friday, March 28 – Saturday, March 29, 2025.
globenewswire.com
- 1 month ago
PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune® HPV in HPV16-Positive Head and Neck Cancer
First-ever HPV16-positive head and neck cancer Phase 3 clinical trial First-ever HPV16-positive head and neck cancer Phase 3 clinical trial
globenewswire.com
- 1 month ago
EMV Capital portfolio company PDS Biotechnology raises $11mln
EMV Capital plc (AIM: EMVC) portfolio company PDS Biotechnology Corporation (Nasdaq: PDSB) has raised $11 million, through an equity funding. PDS, which is focussed on immunotherapies, sold around 7.33 million new shares in a direct offer, plus warrants which (if exercised) will bring in another $11 million.
proactiveinvestors.co.uk
- 1 month ago
PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced it has entered into securities purchase agreements with new and existing healthcare focused institutional investors as well as participation from certain directors of the Company, for the purchase and sale of 7,330,121 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 7,330,121 shares of common stock in a registered direct offering priced at-the-market under Nasdaq rules (the "Offering") at a combined purchase price of $1.50 for the institutional investors and $1.66 for certain directors of the Company.
globenewswire.com
- 1 month ago
PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology
Median Overall Survival (mOS) of 42.4 months in immune checkpoint inhibitor naïve patients; Historical published result is 7-12 months Continued survival in the cohort of HPV16-positive immune checkpoint inhibitor naïve patients - mOS not yet reached Median OS of 17 months in HPV16-positive immune checkpoint inhibitor resistant patients; Historically published result is 3-4 months Significant tumor shrinkage with confirmed objective response rate (ORR) of 75% in HPV16-positive immune checkpoint inhibitor naïve patients; Historically published result is 11-24% PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of clinical results in the Journal of the American Medical Association (JAMA) Oncology.
globenewswire.com
- 1 month ago
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research
Data confirms Versamune ® HPV has potential as a broadly effective treatment of HPV16-associated cancers – Initiation of Phase 3 trial in HPV16-positive HNSCC planned for Q1 2025
globenewswire.com
- 1 month ago
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025
PRINCETON, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech will participate in a fireside chat at the B.
globenewswire.com
- 1 month ago
8. Profile
Summary
PDS Biotechnology Corporation PDSB
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 43.7 M
Dividend Yield
0.00%
Description
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
Contact
25B Vreeland Road, Florham Park, NJ, 07932
https://www.pdsbiotech.com
IPO
Date
Sept. 30, 2015
Employees
24
Officers
Mr. Lars Robert Boesgaard M.B.A.
Principal Financial & Accounting Officer and Chief Financial Officer
Mr. Stephan Toutain M.B.A., M.S.
Chief Operating Officer
Dr. Frank K. Bedu-Addo Ph.D.
President, Chief Executive Officer & Director
Dr. Gregory L. Conn Ph.D.
Chief Scientific Officer
Mr. Spencer Brown J.D.
Senior Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer
Dr. Kirk V. Shepard M.D.
Chief Medical Officer
Ms. Janetta Trochimiuk
Controller